Cargando…

Higher Adalimumab Trough Levels Are Associated with Histologic Remission and Mucosal Healing in Inflammatory Bowel Disease

(1) Many patients with inflammatory bowel disease (IBD) in endoscopic remission have persistent histologic activity, which is associated with worse outcomes. There are limited data on the association between adalimumab drug concentrations and histologic outcomes using validated histologic indices. W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wong, Rochelle, Qin, Lihui, Pan, Yushan, Mahtani, Prerna, Longman, Randy, Lukin, Dana, Scherl, Ellen, Battat, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647216/ https://www.ncbi.nlm.nih.gov/pubmed/37959261 http://dx.doi.org/10.3390/jcm12216796

Ejemplares similares

The Impact of Confounders on Symptom–Endoscopic Discordances in Crohn’s Disease
por: Rajan, Anjana, et al.
Publicado: (2023)

Impact of Inflammatory Bowel Disease Therapies on Durability of Humoral Response to SARS-CoV-2 Vaccination
por: Charilaou, Paris, et al.
Publicado: (2022)

Su1487: IMPACT OF INFLAMMATORY BOWEL DISEASE THERAPIES ON DURABILITY OF HUMORAL RESPONSE TO SARS COV-2 VACCINATION
por: Charilaou, Paris, et al.
Publicado: (2022)

Defining the phenotype, pathogenesis and treatment of Crohn’s disease associated spondyloarthritis
por: Kumar, Anand, et al.
Publicado: (2020)

Prevalence and factors associated with vitamin C deficiency in inflammatory bowel disease
por: Gordon, Benjamin Langan, et al.
Publicado: (2022)

Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn’s disease
por: Gu, Bonita, et al.
Publicado: (2022)

Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease
por: Kumar, Anand, et al.
Publicado: (2020)

Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients
por: Choi, So Yoon, et al.
Publicado: (2020)

No Durable Impact of COVID-19 on Intestinal Disease Activity in Subjects With IBD
por: Lukin, Dana J., et al.
Publicado: (2021)

Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease
por: Lukin, Dana J., et al.
Publicado: (2020)

Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease
por: Kato, Masaichi, et al.
Publicado: (2021)

Mucosal microbiota and gene expression are associated with long-term remission after discontinuation of adalimumab in ulcerative colitis
por: Sakurai, Toshiharu, et al.
Publicado: (2020)

High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study
por: Wilson, Aze, et al.
Publicado: (2021)

Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study
por: Koga, Akihiro, et al.
Publicado: (2018)

Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn’s disease
por: Szymanska, Edyta, et al.
Publicado: (2016)

Can histologic remission be a better prognostic factor and therapeutic target beyond endoscopic mucosal healing in patients with ulcerative colitis?
por: Ahn, Hyo Jun, et al.
Publicado: (2018)

Relationship between endoscopic mucosal healing and histologic inflammation during remission maintenance phase in ulcerative colitis: a retrospective study
por: Kanazawa, Mimari, et al.
Publicado: (2019)

Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn’s Disease
por: Orts, Beatriz, et al.
Publicado: (2022)

Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease
por: Hirayama, Hisashi, et al.
Publicado: (2022)

Remission of hepatotoxicity in chronic pulmonary aspergillosis patients after lowering trough concentration of voriconazole
por: Teng, Guo-Jie, et al.
Publicado: (2020)

Association of sleep quality and mucosal healing in patients with inflammatory bowel disease in clinical remission
por: Michalopoulos, George, et al.
Publicado: (2018)

Joint Disease Activity in Inflammatory Bowel Disease–associated Peripheral Spondyloarthritis Stratifies Therapeutic Response
por: LAI, D., et al.
Publicado: (2022)

Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis
por: Hum, Ryan M, et al.
Publicado: (2022)

Histologic healing and factors associated with complete remission following conventional treatment in ulcerative colitis
por: Steinsbø, Øyvind, et al.
Publicado: (2022)

Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn’s Disease: Results from the EXTEND Trial
por: Reinisch, Walter, et al.
Publicado: (2017)

PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system
por: Gui, Xianyong, et al.
Publicado: (2022)

Serum Ustekinumab Concentrations Are Associated With Remission in Crohn’s Disease Defined by a Serum-Based Endoscopic Healing Index
por: Walshe, Margaret, et al.
Publicado: (2021)

Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab
por: Kimura, Noriko, et al.
Publicado: (2019)

The earliest trough concentration predicts the dose of tacrolimus required for remission induction therapy in ulcerative colitis patients
por: Hiraoka, Sakiko, et al.
Publicado: (2015)

Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease
por: Choi, So Yoon, et al.
Publicado: (2019)

Prostaglandin E‐major urinary metabolite diagnoses mucosal healing in patients with ulcerative colitis in remission phase
por: Sakurai, Toshiyuki, et al.
Publicado: (2022)

Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
por: Mizoshita, Tsutomu, et al.
Publicado: (2016)

2332. Higher Pediatric Vancomycin Dosing Trends Toward Improved Therapeutic Troughs
por: Boeglin, August, et al.
Publicado: (2018)

Positive relationship between infliximab and adalimumab trough levels at completion of induction therapy with clinical response rates, at a tertiary referral center
por: Tighe, Donal, et al.
Publicado: (2017)

Of waves and troughs
por: Noll-Hussong, Michael
Publicado: (2014)

Determination of lower cut‐off levels of adalimumab associated with biochemical remission in Crohn's disease
por: Carlsen, Arne, et al.
Publicado: (2019)

Adalimumab for induction of remission in patients with Crohn's disease: a systematic review and meta-analysis
por: Yin, Juntao, et al.
Publicado: (2022)

Evaluating mucosal healing using colon capsule endoscopy predicts outcome in patients with ulcerative colitis in clinical remission
por: Takano, Ryosuke, et al.
Publicado: (2018)

Normalization of C-Reactive Protein Predicts Better Outcome in Patients With Crohn's Disease With Mucosal Healing and Deep Remission
por: Lin, Xiaoqin, et al.
Publicado: (2020)

Significance of measurement of serum trough level and anti‐drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial
por: Nakase, H., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0rbqaebif619n1383nuctvpr06